Literature DB >> 19496616

Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.

Li Xing1, Huey S Shieh, Shaun R Selness, Rajesh V Devraj, John K Walker, Balekudru Devadas, Heidi R Hope, Robert P Compton, John F Schindler, Jeffrey L Hirsch, Alan G Benson, Ravi G Kurumbail, Roderick A Stegeman, Jennifer M Williams, Richard M Broadus, Zara Walden, Joseph B Monahan.   

Abstract

PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. On the basis of structural comparison with a different biaryl pyrazole template and supported by dozens of high-resolution crystal structures of p38alpha inhibitor complexes, PH-797804 is predicted to possess a high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge: (i) Thr106 that serves as the gatekeeper to the buried hydrophobic pocket occupied by 2,4-difluorophenyl of PH-797804 and (ii) the bidentate hydrogen bonds formed by the pyridinone moiety with the kinase hinge requiring an induced 180 degrees rotation of the Met109-Gly110 peptide bond. The peptide flip occurs in p38alpha kinase due to the critical glycine residue marked by its conformational flexibility. Kinome-wide sequence mining revealed rare presentation of the selectivity motif. Corroboratively, PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. No cross-reactivity was observed in large panels of kinase screens (selectivity ratio of >500-fold). In cellular assays, PH-797804 demonstrated superior potency and selectivity consistent with the biochemical measurements. PH-797804 has met safety criteria in human phase I studies and is under clinical development for several inflammatory conditions. Understanding the rationale for selectivity at the molecular level helps elucidate the biological function and design of specific p38alpha kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496616     DOI: 10.1021/bi900655f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent Cytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative Stress-induced Necrosis.

Authors:  Takeshi Watanabe; Shiori Sekine; Isao Naguro; Yusuke Sekine; Hidenori Ichijo
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

2.  Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.

Authors:  Ken-Ichi Kusakabe; Nobuyuki Ide; Yataro Daigo; Takeshi Itoh; Kenichi Higashino; Yousuke Okano; Genta Tadano; Yuki Tachibana; Yuji Sato; Makiko Inoue; Tooru Wada; Motofumi Iguchi; Takayuki Kanazawa; Yukichi Ishioka; Keiji Dohi; Sachie Tagashira; Yasuto Kido; Shingo Sakamoto; Kazuya Yasuo; Masahiro Maeda; Takahiko Yamamoto; Masayo Higaki; Takeshi Endoh; Kazuo Ueda; Takeshi Shiota; Hitoshi Murai; Yusuke Nakamura
Journal:  ACS Med Chem Lett       Date:  2012-06-06       Impact factor: 4.345

Review 3.  p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes.

Authors:  Ramkumar Menon; John Papaconstantinou
Journal:  Expert Opin Ther Targets       Date:  2016-08-04       Impact factor: 6.902

Review 4.  Chiral kinase inhibitors.

Authors:  Jian-kang Jiang; Min Shen; Craig J Thomas; Mathew B Boxer
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.

Authors:  Lorena Pereira; Ana Igea; Begoña Canovas; Ignacio Dolado; Angel R Nebreda
Journal:  EMBO Mol Med       Date:  2013-09-24       Impact factor: 12.137

6.  A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.

Authors:  Elena Arriazu; Carmen Vicente; Raffaella Pippa; Irene Peris; Elena Martínez-Balsalobre; Patricia García-Ramírez; Nerea Marcotegui; Ana Igea; Diego Alignani; José Rifón; María C Mateos; María L Cayuela; Angel R Nebreda; María D Odero
Journal:  Blood Cancer J       Date:  2020-01-08       Impact factor: 11.037

7.  High-throughput screen to identify compounds that prevent or target telomere loss in human cancer cells.

Authors:  Chris Wilson; John P Murnane
Journal:  NAR Cancer       Date:  2022-10-03

8.  Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.

Authors:  D Martin Watterson; Valerie L Grum-Tokars; Saktimayee M Roy; James P Schavocky; Brinda Desai Bradaric; Adam D Bachstetter; Bin Xing; Edgardo Dimayuga; Faisal Saeed; Hong Zhang; Agnieszka Staniszewski; Jeffrey C Pelletier; George Minasov; Wayne F Anderson; Ottavio Arancio; Linda J Van Eldik
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

9.  Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration.

Authors:  Omkar Chaudhary; Vivek Narayan; Felipe Lelis; Brandon Linz; Meagan Watkins; Ronald Veazey; Anna Aldovini
Journal:  PLoS Pathog       Date:  2018-08-30       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.